Politics Versus Science in Biomedical Research and Development

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-07-02-2004
Volume 28
Issue 7

Decisions to accelerate the approval of AIDS combination drugs, reject the over-the-counter status for the morning-after pill, and limit support for stem cell research are hot political topics.

External Link - article-103357.pdf

Articles in this issue
i1-143861-1408695852146.jpg
3M Drug Delivery Systems
i1-143960-1408695698259.jpg
AccuRate
July 2004
Characterization of the Performance of Bin Blenders Part 2 of 3: Free-Flowing Mixtures
Investors Shy Away from Pharmaceutical Chemicals
From CGMPs to the Critical Path: FDA Focuses on Innovation, Quality, and Continuous Improvement–Inside and Out
In the Spotlight-July 2004
The LR Method in Critical Areas: Airflow Patterns and the Design of Aseptic Interventions
A Stability Program for the Distribution of Drug Products
Politics Versus Science in Biomedical Research and Development
Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

EMA Prepared for Health Technology Assessment Regulation Implementation

Susan Haigney
January 10th 2025
Article

The HTAR, which aims to increase access to new medicines, becomes effective Jan. 12, 2025.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

J&J Gets FDA Fast Track Designation for Alzheimer’s mAb, Posdinemab

Feliza Mirasol
January 9th 2025
Article

Posdinemab is the second tau-directed investigational therapy by J&J that has received fast track designation from FDA this year for Alzheimer’s disease.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Releases Draft Guidance on Sampling and Testing of In-Process Materials and Drug Products

Susan Haigney
January 3rd 2025
Article

The draft guidance document provides recommendations for complying with 21 CFR 211.110.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Announces Reopening of Comment Period Regarding HCP Immunogenicity Risk from Follow-on Recombinant Peptides

Feliza Mirasol
January 3rd 2025
Article

The comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, has been reopened by FDA until March 3, 2025.